Angiogenesis and hepatocellular carcinoma

[91] Clinical translation of angiogenesis inhibitors [J]. NATURE REVIEWS CANCER, 2002, 2 (10) : 727 - 739

[92] Proapoptotic and anti proliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells [J]. HEPATOLOGY, 2002, 36 (04) : 885 - 894

[93] Kim JH, 2001, MOL CELLS, V12, P32

[94] INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-INDUCED ANGIOGENESIS SUPPRESSES TUMOR-GROWTH INVIVO [J]. NATURE, 1993, 362 (6423) : 841 - 844

[95] Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes [J]. NATURE MEDICINE, 2001, 7 (04) : 437 - 443

[96] Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: Correlations with clinical parameters and survival [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (04) : 184 - 190

[97] Kin M, 2000, INT J ONCOL, V16, P375

[98] Angiogenesis inhibitor TNP-470 can suppress hepatocellular carcinoma growth without retarding liver regeneration after partial hepatectomy [J]. SURGERY TODAY, 2004, 34 (01) : 40 - 46

[99] Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (08) : R15 - R24

[100] Klement G, 2002, CLIN CANCER RES, V8, P221

[91] Clinical translation of angiogenesis inhibitors [J]. NATURE REVIEWS CANCER, 2002, 2 (10) : 727 - 739

[92] Proapoptotic and anti proliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells [J]. HEPATOLOGY, 2002, 36 (04) : 885 - 894

[93] Kim JH, 2001, MOL CELLS, V12, P32

[94] INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-INDUCED ANGIOGENESIS SUPPRESSES TUMOR-GROWTH INVIVO [J]. NATURE, 1993, 362 (6423) : 841 - 844

[95] Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes [J]. NATURE MEDICINE, 2001, 7 (04) : 437 - 443

[96] Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: Correlations with clinical parameters and survival [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (04) : 184 - 190

[97] Kin M, 2000, INT J ONCOL, V16, P375

[98] Angiogenesis inhibitor TNP-470 can suppress hepatocellular carcinoma growth without retarding liver regeneration after partial hepatectomy [J]. SURGERY TODAY, 2004, 34 (01) : 40 - 46

[99] Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (08) : R15 - R24

[100] Klement G, 2002, CLIN CANCER RES, V8, P221